Skip to main content

Table 1 Number of participants that with metabolic related disorders before and after intervention

From: Coenzyme Q10 supplementation improves adipokine profile in dyslipidemic individuals: a randomized controlled trial

Disorders
n (%)
Placebo (n = 50) CoQ10 (n = 51) p3c p4d
Baseline 24-week p1a Baseline 24-week p2b
Prediabetese 32
(64.0)
30
(60.0)
0.680 25
(49.0)
13
(25.5)
0.014 0.125  < 0.001
IRf 49
(98.0)
47
(94.0)
0.307 49
(96.1)
40
(78.4)
0.008 0.570 0.024
Metsg 30
(60.0)
28
(56.0)
0.685 35
(68.6)
18
(35.3)
0.001 0.365 0.037
  1. ap1 values were calculated by chi-square tests for differences between baseline and 24th week in placebo groups
  2. bp2 values were calculated by chi-square tests for differences between baseline and 24th week in CoQ10 groups
  3. cp3 values were calculated by chi-square tests for differences between two group at baseline
  4. dp4 values were calculated by chi-square tests for differences between two group at 24th week
  5. eDefined as 7.0 > fast blood glucose ≥ 5.6 mmol/L or 126 > fast blood glucose ≥ 100.8 mg/dL
  6. fIR, insulin resistance, define as HOMA-IR index > 1
  7. gMets, metabolic syndromes, defined according to National Cholesterol Education Program Adult Treatment Panel III (2005 American Heart Association revised edition) definition